Ownership and insider activity for Larimar Therapeutics, Inc. (LRMR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials.
Price
| Price | $3.93 |
| Market Cap | $408M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.4M | $40.8M | $49.3M | $1.0M | $68.1M | $70.1M | $26.8M | $26.7M | $33.2M | $85.4M |
| Short-term Investments | $96.8M | $61.3M | $68.7M | 0 | $24.5M | 0 | $91.6M | $60.0M | $150.2M | $51.4M |
| Receivables | $347000 | $946000 | $1.5M | $158000 | $32000 | $208000 | 0 | $332000 | $1.1M | $747000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $130.9M | $104.9M | $121.3M | $4.8M | $98.0M | $72.2M | $120.7M | $90.2M | $195.3M | $142.0M |
| Property, Plant & Equipment | $661000 | $528000 | $375000 | $361000 | $5.0M | $4.5M | $3.7M | $3.8M | $3.7M | $2.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $131.6M | $105.5M | $121.8M | $5.2M | $104.7M | $78.7M | $126.4M | $95.9M | $200.2M | $145.8M |
| Accounts Payable | 0 | 0 | $909000 | $3.5M | $2.6M | $1.7M | $1.7M | $1.3M | $2.4M | $5.2M |
| Short-term Debt | $3.6M | 0 | $5.5M | 0 | 0 | 0 | 0 | 0 | 0 | $1.1M |
| Total Current Liabilities | $9.9M | $7.3M | $13.3M | $5.9M | $9.0M | $8.8M | $10.7M | $9.5M | $24.4M | $64.8M |
| Long-term Debt | 0 | $20.0M | $15.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $9.9M | $27.3M | $28.5M | $5.9M | $15.0M | $14.3M | $15.5M | $14.2M | $28.4M | $67.8M |
| Retained Earnings | -$237.5M | -$289.6M | -$350.9M | -$23.1M | -$65.6M | -$116.2M | -$151.6M | -$188.6M | -$269.2M | -$434.8M |
| Total Equity | $121.7M | $78.2M | $93.3M | -$694000 | $89.7M | $64.4M | $110.9M | $81.7M | $171.8M | $78.1M |
| Total Debt | $3.6M | $20.0M | $20.6M | $97000 | $6.5M | $6.0M | $5.4M | $5.5M | $5.1M | $4.1M |
| Net Debt | -$125.6M | -$82.1M | -$97.4M | -$912000 | -$86.1M | -$64.1M | -$113.0M | -$81.2M | -$178.3M | -$132.8M |
| Working Capital | $121.0M | $97.6M | $108.0M | -$1.1M | $89.0M | $63.4M | $110.0M | $80.7M | $170.9M | $77.2M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 4.70 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -4.98 |
Profitability
| Return on Equity | -137.39% |
| Return on Invested Capital | -135.25% |
| Return on Assets | -104.42% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALT · AMRN · ANNX · ANRO · DBVT · ENGN
Explore sector: Healthcare · Biotechnology
More sections of LRMR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks